Related Experiment Video
Updated: Jun 19, 2026
08:29
Reinstatement of Drug-seeking in Mice Using the Conditioned Place Preference Paradigm
Published on: June 7, 2018
Provider incentives and prescribing behavior in Europe
Elias Mossialos1, Tom Walley, Caroline Rudisill
1London School of Economics, Health and Social Care, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK. e.a.mossialos@lse.ac.uk
Expert Review of Pharmacoeconomics & Outcomes Research
|October 8, 2009
Summary
European healthcare policy increasingly uses provider incentives to manage pharmaceutical costs. Effective policy requires clear objectives and ethical considerations for prescribing behavior.
Area of Science:
- Health Policy
- Pharmaceutical Economics
Background:
- European healthcare systems are shifting from supply-side regulation to provider-focused policies for pharmaceutical cost control.
- These provider incentives vary significantly across different national health systems.
- Policy implementation has evolved with changing health system designs and practical experience.
Purpose of the Study:
- To analyze the evolution and diversity of provider-focused pharmaceutical cost-containment policies in European countries.
- To identify key considerations for designing and evaluating these incentive-based policies.
Main Methods:
- Comparative analysis of European healthcare policy approaches.
- Review of policy alterations and practical outcomes.
- Examination of challenges in evaluating prescribing incentive programs due to data limitations.
Main Results:
- Prescribing incentive policies are diverse and have been modified over time.
- Comprehensive prescription tracking systems are often lacking, hindering policy evaluation.
- Policy effectiveness is influenced by clarity of objectives and ethical considerations.
Conclusions:
- Future pharmaceutical cost-containment policies should prioritize clear objectives and transparency.
- Ethical concerns regarding financial incentives and physician autonomy must be addressed.
- Robust information systems are crucial for effective evaluation of prescribing behavior interventions.
Related Concept Videos
01:02Prescription, Nonprescription and Orphan Drugs
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:18Incentive Theory: Pull Theory of Motivation
Incentive theory, or the "pull theory" of motivation, suggests that external rewards primarily drive behavior. Individuals are motivated to engage in activities when they anticipate a desirable outcome. This is why people often work hard for promotions or study intensively to achieve high grades. These incentives can be tangible, physical rewards such as money or promotions, or intangible, non-physical rewards like praise and social recognition.
The theory differentiates between intrinsic and...
The theory differentiates between intrinsic and...
01:15Drug Abuse and Addiction: Pharmacological Phenomena
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...